© 2022 MJH Life Sciences and HCPLive - Clinical news for connected physicians. All rights reserved.
© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
Updated recommendations to managing type 2 diabetes with SGLT2 inhibitors and GLP-1 receptor agonists and preventing cardiovascular events.
December 21st 2021
A call to action for more focus on the management of the type 2 diabetes epidemic around the globe.
Updated guideline recommendations regarding the monitoring and management of patients’ blood pressure levels to reduce the risk of cardiovascular events.
January 4th 2022
Considerations that factor into decisions for reducing LDL levels in patients with diabetes with statin therapy or options, such as PCSK9 inhibitors and ezetimibe.
How to best prevent and manage statin-associated myalgias when managing cholesterol levels in patients with type 2 diabetes at risk for cardiovascular events.
January 11th 2022
Guidance on the use of aspirin therapy in patients at risk of cardiovascular events, based on recently updated guideline recommendations.
Takeaways of the most recent ADA guidelines in terms of treating patients with diabetes with metformin, SGLT2 inhibitors, and GLP-1 receptor agonists.
January 18th 2022
The benefits of using new therapies, such as SGLT2 inhibitors and GLP-1 receptor agonists, to treat type 2 diabetes.
A discussion on using continuous glucose monitoring systems to improve the management of type 2 diabetes.